Literature DB >> 30070335

Combining clinical predictors to better predict for the no-reflow phenomenon.

E Avci1, T Yildirim, G Aydin, T Kiris, A Dolapoglu, H Kadi, O Safak, S Bayata.   

Abstract

OBJECTIVE: We aimed to determine whether the combination of a CHA2DS2-VASc score (C: Congestive Heart Failure, H: Hypertension, A2: Age ≥ 75 years, D: Diabetes mellitus, S: Stroke history, V: Vascular disease, A: Age ≥ 65 years, Sc: Sex category) and pre-percutaneous coronary intervention (PCI) thrombus load score was more sensitive at detecting the no-reflow phenomenon compared to the CHA2DS2-VASc score alone or to the thrombus load score alone in patients with acute ST-elevation myocardial infarction (STEMI) who had underwent primary PCI (PPCI). PATIENTS AND METHODS: 497 patients with acute STEMIs were divided into two groups: no-reflow group (n: 194) and control group (n: 303). The Thrombolysis In Myocardial Infarction (TIMI) flow grading and Myocardial Blush Grade (MBG) were used together to define angiographic no-reflow as TIMI flow < 3 (with any MBG grade) or TIMI flow 3 with MBG 0 or 1. Successful reperfusion was defined as TIMI flow 3 with MBG 2 or 3.
RESULTS: CHA2DS2-VASc score was significantly higher in the no-reflow group than in the control group (2 [1-4] vs. 1 [0-3], p < 0.001]. Compared with the control group, the no-reflow group had a higher pre-PCI thrombus score (5 [4-5] vs. 4 [3-5], p = 0.001). Compared with the CHA2DS2-VASc score alone, the combined use of the pre-PCI thrombus score and the CHA2DS2-VASc score was associated with significant improvements in the ability to predict no-reflow (AUC) (0.65 vs. 0.60, p < 0.05). The addition of the pre-PCI thrombus score to the CHA2DS2-VASc score was related to a significant net reclassification improvement of 6.7% (p = 0.047) and an integrated discrimination improvement of 0.036 (p < 0.05).
CONCLUSIONS: We have found that the combination of a CHA2DS2-VASc score and a pre-PCI thrombus load score was more sensitive in detecting the no-reflow phenomenon than only a CHA2DS2-VASc score in patients who underwent PPCIs for STEMIs.

Entities:  

Mesh:

Year:  2018        PMID: 30070335     DOI: 10.26355/eurrev_201808_15639

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Presence of Microvascular Dysfunction and CHA2DS2-VASc Score in Patients with ST-Segment Myocardial Infarction after Primary Percutaneous Coronary Intervention.

Authors:  Ragab A Mahfouz; Marwa M Gad; Mohamed Arab; Moei-E Deen Abulfotouh
Journal:  Pulse (Basel)       Date:  2021-11-26

2.  Association of CHA2DS2-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI.

Authors:  Orhan Maden; Özge Çakmak Karaaslan; Yücel Kanal; İdris Yakut; Nezaket Merve Yaman; Hasan Can Könte; Kevser Gülcihan Balcı; Mehmet Timur Selçuk; Hatice Selçuk
Journal:  Herz       Date:  2021-10-04       Impact factor: 1.740

3.  New CHA2DS2-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.

Authors:  Qin-Yao Zhang; Shu-Mei Ma; Jia-Ying Sun
Journal:  BMC Cardiovasc Disord       Date:  2020-07-25       Impact factor: 2.298

4.  Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Li Yang; Hongliang Cong; Yali Lu; Xiaolin Chen; Yin Liu
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

5.  Intracoronary and peripheral blood levels of TNF-like Cytokine 1A (TL1A) in patients with acute coronary syndrome.

Authors:  Xinjing Chen; Yansong Guo; Li Lai; Shengli Zhang; Zhiliang Li
Journal:  Medicine (Baltimore)       Date:  2020-05-29       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.